MannKind Corporation Reports 2010 Second Quarter Financial Results
VALENCIA, Calif., Aug 02, 2010 (BUSINESS WIRE) --
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2010.
For the second quarter of 2010 total operating expenses were $37.4 million, compared to $53.4 million for the second quarter of 2009, a decrease of $16.0 million. Research and development (R&D) expenses were $26.2 million for the second quarter of 2010 compared to $39.8 million for the same quarter in 2009, a decrease of $13.7 million. This 34% decrease in R&D expense was primarily due to reduced costs associated with the clinical development of AFREZZA after the submission of its NDA in March 2009. General and administrative (G&A) expenses decreased by $2.3 million to $11.2 million for the second quarter of 2010 compared to $13.5 million in the second quarter of 2009. This 17% decrease in G&A expense was mainly due to decreased salary related costs resulting from the April 2009 reduction in force and the non-recurrence of professional fees related to the insulin acquisition transaction with Pfizer, which was completed during the second quarter of 2009.
For the first six months of 2010, operating expenses totaled $78.0 million, compared to $111.2 million in the first half of 2009. R&D expenses for the first six months of 2010 were $56.7 million, compared to $82.7 million in the first six months of 2009, a decrease of $26.1 million. The 32% decrease in R&D expenses for the first six months of 2010 was primarily due to decreased costs associated with the clinical development of AFREZZA after the submission of its NDA in March 2009, as well as decreases in clinical supplies costs. G&A expenses decreased by $7.1 million or 25% to $21.3 million for the first half of 2010 as compared to $28.5 million in the same period in 2009. The decrease in G&A expenses for the first six months of 2010 was primarily due to decreased salary related costs resulting from the April 2009 reduction in force and the non-recurrence of professional fees related to the negotiation and completion of the insulin acquisition transaction with Pfizer during the first half of 2009.
The net loss applicable to common stockholders for the second quarter of 2010 was $42.3 million, or $0.37 per share based on 113.1 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $55.6 million, or $0.54 per share based on 102.3 million weighted average shares outstanding for the second quarter of 2009. The number of common shares outstanding at June 30, 2010 was 113,674,221.
The net loss for the first half of 2010 was $87.0 million, or $0.77 per share based on 113.1 million weighted average shares outstanding, compared with a net loss of $115.0 million, or $1.13 per share based on 102.2 million weighted average shares outstanding, for the first half of 2009.
Cash, cash equivalents and marketable securities were $30.8 million at June 30, 2010 and $32.5 million at December 31, 2009. As of June 30, 2010, the Company had $108.0 million of available borrowings under the loan agreement with an entity controlled by the Company's principal stockholder.
"The second quarter was particularly busy, as we prepared for our meeting with the FDA and then submitted our response to the agency's Complete Response letter of March 2010," said Alfred Mann, Chairman and Chief Executive Office of MannKind Corporation. "With a Class 2 designation for this resubmission, our focus for the next six months will be to work closely with the FDA as it evaluates our next-generation delivery system and the other information that we provided in our resubmission. In the coming months, we will also initiate the installation and validation of equipment for the new device in our Danbury, Connecticut manufacturing facility. Everyone at MannKind is committed to the goal of making AFREZZA available to patients as soon as possible."
MannKind management will host a conference call to discuss these results today at 9:00 a.m. Eastern Time. To participate in the call please dial (888) 677-5721 or (210) 839-8507 and use the participant passcode: MANNKIND. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (888) 568-0802 or (203) 369-3929.
Presenting from the Company will be:
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZATM and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
This press release contains forward-looking statements, including statements related to available borrowings under MannKind's loan agreement, future interactions with the FDA and the regulatory status of MannKind's product candidates, that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, difficulties or delays in seeking or obtaining regulatory approval, MannKind's ability to manage its existing cash resources or raise additional cash resources, stock price volatility and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2009 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
Three months ended
Six months ended
from February 14,
1991 (date of
|Research and development||26,160||39,849||56,651||82,738||1,210,464|
|General and administrative||11,196||13,537||21,306||28,454||320,595|
|In-process research and development costs||--||--||--||--||19,726|
|Total operating expenses||37,356||53,386||77,957||111,192||1,702,213|
|Loss from operations||(37,263||)||(53,386||)||(77,864||)||(111,192||)||(1,699,132||)|
|Other (expense) income||(1,257||)||283||(2,047||)||353||(3,939||)|
|Interest expense on note payable to related party||(2,523||)||(1,398||)||(4,625||)||(1,990||)||(11,827||)|
|Interest expense on senior convertible notes||(1,211||)||(1,130||)||(2,421||)||(2,245||)||(13,146||)|
|Loss before provision for income taxes||(42,251||)||(55,604||)||(86,951||)||(115,016||)||(1,691,107||)|
Deemed dividend related to beneficial conversion feature of convertible preferred stock
|Accretion on redeemable preferred stock||--||--||--||--||(952||)|
|Net loss applicable to common stockholders||$||(42,251||)||$||(55,604||)||$||(86,951||)||$||(115,016||)||$||(1,714,345||)|
Net loss per share applicable to common stockholders -- basic and diluted
Shares used to compute basic and diluted net loss per share applicable to common stockholders
(A Development Stage Company)
Condensed Consolidated Balance Sheet
June 30, 2010
December 31, 2009
|Cash and cash equivalents||$||28,358||$||30,019|
|State research and development credit exchange receivable -- current||--||1,500|
|Prepaid expenses and other current assets||2,451||3,672|
|Total current assets||33,223||37,666|
|Property and equipment -- net||204,398||208,229|
|State research and development credit exchange receivable -- net of current portion||1,352||918|
Liabilities and Stockholders' Deficit
|Senior convertible notes||113,030||112,765|
|Note payable to related party||242,000||165,000|
SOURCE: MannKind Corporation
Matthew J. Pfeffer
Chief Financial Officer